A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)
PHASE3CompletedINTERVENTIONAL
Enrollment
132
Participants
Timeline
Start Date
October 31, 2013
Primary Completion Date
October 31, 2015
Study Completion Date
October 31, 2015
Conditions
Type 2 DM Patients With Moderate or Severe Renal Impairment